BMP2/BMPR1A is linked to tumour progression in dedifferentiated liposarcomas.
Bone Morphogenic Protein 2 (BMP2) is a multipurpose cytokine, important in the development of bone and cartilage, and with a role in tumour initiation and progression. BMP2 signal transduction is dependent on two distinct classes of serine/threonine kinase known as the type I and type II receptors. Although the type I receptors (BMPR1A and BMPR1B) are largely thought to have overlapping functions, we find tissue and cellular compartment specific patterns of expression, suggesting potential for distinct BMP2 signalling outcomes dependent on tissue type. Herein, we utilise large publicly available datasets from The Cancer Genome Atlas (TCGA) and Protein Atlas to define a novel role for BMP2 in the progression of dedifferentiated liposarcomas. Using disease free survival as our primary endpoint, we find that BMP2 confers poor prognosis only within the context of high BMPR1A expression. Through further annotation of the TCGA sarcoma dataset, we localise this effect to dedifferentiated liposarcomas but find overall BMP2/BMP receptor expression is equal across subsets. Finally, through gene set enrichment analysis we link the BMP2/BMPR1A axis to increased transcriptional activity of the matrisome and general extracellular matrix remodelling. Our study highlights the importance of continued research into the tumorigenic properties of BMP2 and the potential disadvantages of recombinant human BMP2 (rhBMP2) use in orthopaedic surgery. For the first time, we identify high BMP2 expression within the context of high BMPR1A expression as a biomarker of disease relapse in dedifferentiated liposarcomas.
Aberdeen Royal Infirmary, University of Aberdeen , Aberdeen , United Kingdom.
Hannah L
HL
O'Neill
Aberdeen Royal Infirmary, University of Aberdeen, Aberdeen, United Kingdom; Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom.
Amy P
AP
Cassidy
Wellcome Trust-MRC Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom; Department of Pathology, University of Cambridge, Cambridge, United Kingdom.
Olivia B
OB
Harris
Queens' College, University of Cambridge, Cambridge Cambridgeshire, United Kingdom; Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.
John W
JW
Cassidy
Bone engineering; Bone morphogenic protein; Bone repair; Dedifferentiated liposarcomas; Orthopaedic surgery; Soft tissue sarcomas; Tissue engineering